Skip to main content

Table 3 Determinants of progression-free survival after BCNU treatment of recurrent glioblastoma (n = 34, 30 events)

From: BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors

   Hazard ratio* 95% confidence interval p-value
Age (years) ≤ 53 vs. > 53 (the median) 1.12 0.41-2.98 0.844
Tumor size (mm2) ≤ 736 vs. > 736 (the median) 0.46 0.15-1.42 0.177
  not measurable vs. > 736 0.45 0.16-1.28 0.135
Karnofsky performance score ≤ 70 vs. 80 or 90 0.50 0.20-1.26 0.143
Surgery Complete resection vs. biopsy/partial resection 3.11 1.02-9.52 0.047
Pre-treatment with temozolomide yes vs. no 1.30 0.43-3.91 0.641
Previous relapses 1 vs. more than 1 0.48 0.14-1.61 0.232
  1. * A hazard ratio <1 (>1) indicates an effect in favor of the first (the second) group in terms of progression-free survival.